A DNA microarray can be referred to as a DNA chip or biochip. This technology refers to a collection of microscopic DNA spots attached to a solid surface. Scientists typically use microarrays to measure the expression levels of large numbers of genes simultaneously or to genotype multiple regions of a genome. So how is this technology relevant to bioprinting? We will go through this intriguing technology and how it affects bioprinting as a whole.
In terms of bioprinting, we must classify microarray bioprinting. Microarray bioprinting refers to printing cells encapsulated in hydrogels in a spatially addressable manner using automated liquid dispensing robots such as microarray spotters. An automated liquid dispensing robot refers to pipetting as well as pumping procedures done through machine automation. One can think of typical bioprinting setups with programmable syringe pumps. Microarray spotters refer to the robotic instruments used for making microarrays. This technology deposits (or “spots”) cDNA probes onto a microscope slide or other substrate. In genetics, complementary DNA (cDNA) is DNA synthesized from a single-stranded RNA (e.g., messenger RNA (mRNA) or microRNA) template in a reaction catalyzed by the enzyme reverse transcriptase. Cells are usually within the nanoliter volume (30 – 60nL) and can be dispensed onto functionalized glass slides or micropillar/microwell chip platforms. This is directly related to our previous article on DNA and how we talked about microfluidics. These cells can be grown in growth media to support miniaturized 3D cell cultures for toxicology assays. Toxicology assays are important in terms of bioprinting because one wants to make sure beforehand that the material being printed will not be detrimental or toxic to the body.
The microwell chip mentioned previously can accommodate up to 950 nL of compounds, recombinant viruses, growth factors, and fluorescent dyes for various cell-based assays. Since the micropillar chip is complementary to the microwell chip, cells on the micropillars can be exposed to hundreds of different test conditions in the microwells simultaneously by simply sandwiching the two chips together. The cells on the micropillar chip can be exposed to compounds for a period of time and stained with fluorescent dyes or fluorescently labeled antibodies to assess drug efficacy and toxicity. Compared to traditional 2D cell monolayer cultures, microarray bioprinting offers several attractive features, including physiologically relevant cells grown in 3D, miniaturization of cell-based assays saving valuable raw materials, such as primary human cells obtained from patients, and ultrahigh-throughput capability of testing cell culture conditions.
It is important to outline why physiologically relevant cell growth in 3D, miniaturization of cell-based assays, and ultrahigh-throughput capability of testing cell culture conditions are very important within microarray based bioprinting. In terms of microfluidics, the various cell structures in the human body must be vascularized to receive the nutrients and gas exchange help that they need to survive. Similarly, 3D cell cultures in vitro require certain levels of fluid circulation, which can be problematic for dense, 3D cultures where cells may not all have adequate exposure to nutrients. This is particularly important in hepatocyte cultures because the liver is a highly vascularized organ. Miniaturization of cell-based assays allows for rapid prototyping as well as low cost implementation within bioprinting processes. High-throughput screening (HTS) is a method for scientific experimentation especially used in drug discovery and relevant to the fields of biology and chemistry. Using robotics, data processing/control software, liquid handling devices, and sensitive detectors, high-throughput screening allows a researcher to quickly conduct millions of chemical, genetic, or pharmacological tests. Being able to do this in vitro allows us to feel more confident in the what is being used within the body in terms of bioprinting.
Microarray bioprinting is a promising high-throughput approach for miniaturized 3D cell cultures. The reduction in sample volume and the speed of printing hundreds of samples in a short period of time make this technology suitable for wide ranges of cell-based assays. The biggest issue is learning how to control these microenvironments enabled by microarray bioprinting.
You May Also Like
Digilab: On the State of Bioprinting Today
In a recent interview with Digilab‘s CEO Sidney Braginsky, Senior Applications Manager Igor Zlatkin, and John Moore, President and COO, 3DPrint.com got a glimpse of the focus, future, and advances...
Wikifactory’s Docubot Challenge Creates a Hardware Solution for Documentation
International startup Wikifactory, established in Hong Kong last June, is a social platform for collaborative product development. Co-founded by four makers, and until recently counting 3DPrint.com Editor-in-Chief Joris Peels as a member...
Kickstarter Campaign Continues for High-Resolution Jewelry 3D Scanner
Ukrainian company D3D-s was founded four years ago by father and son team Leonid and Denys Nazarenko, and last year they successfully raised $250,000 through Kickstarter for their first desktop 3D...
Interview with Formalloy’s Melanie Lang on Directed Energy Deposition
When I met Melanie Lang at RAPID a lot of the buzz on the show floor was directed at her startup Formalloy. Formalloy has developed a metal deposition head that...
View our broad assortment of in house and third party products.